Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BMP Pharma Trading AGSTU:BMP 36 EV-to-EBIT is 8.52 as of Aug. 01, 2026, which is 1% below its 10-year median of 8.61. GuruFocus rates STU:BMP with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 94 Medical Distribution companies, BMP Pharma Trading AG ranks better than 62.77% on this metric.
BMP Pharma Trading AG (STU:BMP) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
BMP Pharma Trading AG's Enterprise Value for the quarter that ended in Dec. 2025 was €27.25 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BMP Pharma Trading AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, BMP Pharma Trading AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BMP Pharma Trading AG EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, BMP Pharma Trading AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where BMP Pharma Trading AG's EV-to-EBIT falls into.
BMP Pharma Trading AG's current Enterprise Value is €32.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BMP Pharma Trading AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €3.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMP Pharma Trading AG (STU:BMP) has a EV-to-EBIT of 8.52 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BMP Pharma Trading AG and its competitors. This is near median its historical median of 8.61. Over the past decade, BMP Pharma Trading AG's EV-to-EBIT has ranged from 2.10 to 33.67. According to the industry distribution chart, BMP Pharma Trading AG ranks #35 out of 94 companies in the Medical Distribution industry, placing it in the top 37.2%.
Is BMP Pharma Trading AG's EV-to-EBIT too high?
BMP Pharma Trading AG's current EV-to-EBIT of 8.52 is near median its 10-year median of 8.61. Over the past 10 years, this metric has ranged from a low of 2.10 to a high of 33.67. The Medical Distribution industry median EV-to-EBIT is 11.71. BMP Pharma Trading AG's value of 8.52 is 27.2% below this industry median. Based on the distribution chart, BMP Pharma Trading AG ranks #35 out of 94 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, BMP Pharma Trading AG has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does BMP Pharma Trading AG's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, BMP Pharma Trading AG ranks #35 out of 94 companies for EV-to-EBIT. This puts BMP Pharma Trading AG in the upper half of its industry. The industry median EV-to-EBIT is 11.71. BMP Pharma Trading AG's value of 8.52 is 27.2% below this benchmark. Historically, BMP Pharma Trading AG's own EV-to-EBIT has ranged from 2.10 to 33.67 over the past decade. While the company's 10-year median is 8.61 vs. the industry median of 11.71, BMP Pharma Trading AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.71, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BMP Pharma Trading AG's current EV-to-EBIT of 8.52 is 27.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on BMP Pharma Trading AG and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BMP Pharma Trading AG's current EV-to-EBIT is 8.52, which is near median its own 10-year median of 8.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BMP Pharma Trading AG stock overvalued right now?
BMP Pharma Trading AG (STU:BMP) has a current EV-to-EBIT of 8.52. The current EV-to-EBIT is 8.52, which is near median its 10-year median of 8.61 and 27.2% below the Medical Distribution industry median of 11.71. BMP Pharma Trading AG's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For BMP Pharma Trading AG (STU:BMP), the current EV-to-EBIT is 8.52 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BMP Pharma Trading AG is a German company engaged in trading of pharmaceutical raw materials, food supplement products, and veterinary raw materials. The services offered by the company include development of microbial processes, Transfer of biotechnological processes, Contract production of biotechnologically and biocatalysts and development of chiral syntheses.
36GF Score
Get the complete analysis for STU:BMP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BMP has been successfully added to your 
